德适生物港股IPO招股书失效

Group 1 - The core viewpoint of the news is that Hangzhou Deshi Biotechnology Co., Ltd. submitted its Hong Kong IPO prospectus on June 29, which became invalid after six months on December 29, with Huatai International serving as the sole sponsor [1] - The prospectus indicates that Deshi Biotechnology's self-developed iMedImageTM is the largest general-purpose medical imaging base model in terms of parameter scale globally, which has been successfully commercialized [2] - iMedImageTM is recognized as the world's first commercialized cross-modal medical imaging base model [2]